TITLE

18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies

AUTHOR(S)
Chin, B. B.; Wahi, R. L.
PUB. DATE
June 2003
SOURCE
Gut;Jun2003 Supplement 4, Vol. 52, piv23
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Positron emission tomography with 18F-fluoro-2-deoxyglucose is an imaging technology that is demonstrating increasing utility in the evaluation of gastrointestinal malignancies.
ACCESSION #
12915405

 

Related Articles

  • Case report: drug interference with MIBG uptake in a patient with metastatic paraganglioma. Zaplatnikov, K.; Menzel, C.; Döbert, N.; Hamscho, N.; Kranert, W. T.; Gotthard, M.; Behr, T. M.; Grünwald, F. // British Journal of Radiology;Jun2004, Vol. 77 Issue 918, p525 

    Metaiodobenzylguanidine (MIBG) labelled with iodine-131 ((131)I) has become a well established therapeutic tool for inoperable metastastic tumours of paraganglioma. There are different pharmacological substances known to interfere with MIBG-uptake which may result in a false negative MIBG scan....

  • The Role for PET Scanning in Breast Cancer Staging. Ershler, William B. // Clinical Oncology Alert;Aug2008, Vol. 24 Issue 8, p62 

    The article discusses research on the role of positron emission tomography (PET) scanning in determining the stage of Breast cancer for patients in whom recurrent disease is suspected. It references a study by S. Mahner et al, published in "Annals of Oncology." PET, using 2-[fluorine-18]...

  • Multimodality imaging in Europe: a survey by the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR). Cuocolo, Alberto; Breatnach, Éamann // European Journal of Nuclear Medicine & Molecular Imaging;Jan2010, Vol. 37 Issue 1, p163 

    Multimodality imaging represents an area of rapid growth with important professional implication for both nuclear medicine physicians and radiologists throughout Europe. As a preliminary step for future action aimed at improving the quality and accessibility of PET/SPECT/CT multimodality imaging...

  • FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Boellaard, Ronald; O'Doherty, Mike; Weber, Wolfgang; Mottaghy, Felix; Lonsdale, Markus; Stroobants, Sigrid; Oyen, Wim; Kotzerke, Joerg; Hoekstra, Otto; Pruim, Jan; Marsden, Paul; Tatsch, Klaus; Hoekstra, Corneline; Visser, Eric; Arends, Bertjan; Verzijlbergen, Fred; Zijlstra, Josee; Comans, Emile; Lammertsma, Adriaan; Paans, Anne // European Journal of Nuclear Medicine & Molecular Imaging;Jan2010, Vol. 37 Issue 1, p181 

    The aim of this guideline is to provide a minimum standard for the acquisition and interpretation of PET and PET/CT scans with [18F]-fluorodeoxyglucose (FDG). This guideline will therefore address general information about [18F]-fluorodeoxyglucose (FDG) positron emission tomography-computed...

  • Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT. Prasad, Vikas; Ambrosini, Valentina; Hommann, Merten; Hoersch, Dieter; Fanti, Stefano; Baum, Richard // European Journal of Nuclear Medicine & Molecular Imaging;Jan2010, Vol. 37 Issue 1, p67 

    This bi-centric study aimed to determine the role of receptor PET/CT using 68Ga-DOTA-NOC in the detection of undiagnosed primary sites of neuroendocrine tumours (NETs) and to understand the molecular behaviour of the primarily undiagnosed tumours. Overall 59 patients (33 men and 26 women, age:...

  • Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Conry, Brendon; Papathanasiou, Nikolaos; Prakash, Vineet; Kayani, Irfan; Caplin, Martyn; Mahmood, Shahid; Bomanji, Jamshed // European Journal of Nuclear Medicine & Molecular Imaging;Jan2010, Vol. 37 Issue 1, p49 

    This was a retrospective study to detect and map the extent of disease in recurrent medullary thyroid carcinoma (MTC) using the novel PET somatostatin analogue 68Ga-DOTATATE and conventional 18F-FDG positron emission tomography/computed tomography (PET/CT). Eighteen patients (13 men, 5 women,...

  • Validation of cardiac 123I-MIBG scintigraphy in patients with Parkinson’s disease who were diagnosed with dopamine PET. Ishibashi, Kenji; Saito, Yuko; Murayama, Shigeo; Kanemaru, Kazutomi; Oda, Keiichi; Ishiwata, Kiichi; Mizusawa, Hidehiro; Ishii, Kenji // European Journal of Nuclear Medicine & Molecular Imaging;Jan2010, Vol. 37 Issue 1, p3 

    The aim of this study was to evaluate the diagnostic potential of cardiac 123I-labelled metaiodobenzylguanidine (123I-MIBG) scintigraphy in idiopathic Parkinson’s disease (PD). The diagnosis was confirmed by positron emission tomography (PET) imaging with 11C-labelled...

  • Diagnostic value of [18F]-FDG PET/CT in children with fever of unknown origin or unexplained signs of inflammation. Jasper, Niklas; Däbritz, Jan; Frosch, Michael; Loeffler, Markus; Weckesser, Matthias; Foell, Dirk // European Journal of Nuclear Medicine & Molecular Imaging;Jan2010, Vol. 37 Issue 1, p136 

    Fever of unknown origin (FUO) and unexplained signs of inflammation are challenging medical problems especially in children and predominantly caused by infections, malignancies or noninfectious inflammatory diseases. The aim of this study was to assess the diagnostic value of 18F-FDG PET and...

  • Iatrogenic FDG foci in the lungs: a pitfall of PET image interpretation. Hany, Thomas F.; Heuberger, Juerg; von Schulthess, Gustav K. // European Radiology;Sep2003, Vol. 13 Issue 9, p2122 

    2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) has become an important staging modality for many tumors, including bronchial carcinoma; however it is important to know that there are several pitfalls in PET image interpretation. In this report we demonstrate three...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics